Brise rais­es $20M; Taro share­hold­er crit­i­cizes Sun Phar­ma deal

Plus, news about Tar­sus Phar­ma­ceu­ti­cals and Bio­haven:

Brise Phar­ma­ceu­ti­cals rais­es $20M: The fund­ing comes from Shunxi Fund, Sher­pa Health­care Part­ners and Qim­ing Ven­tures, among oth­er in­vestors. The Shang­hai-based com­pa­ny is de­vel­op­ing ther­a­pies for acute and chron­ic pain. It be­gan an ear­ly-stage clin­i­cal study of a chron­ic low back pain treat­ment in the US last year. — Lei Lei Wu

Taro share­hold­er rebels against Sun Phar­ma’s buy­out of­fer: Kren­sav­age As­set Man­age­ment — Taro Phar­ma­ceu­ti­cal In­dus­tries’ largest mi­nor­i­ty share­hold­er — said the gener­ics mak­er’s pro­posed buy­out is based “on an in­vest­ment bank’s flawed analy­sis.” Back in Jan­u­ary, Sun an­nounced it would con­vert its ma­jor­i­ty own­er­ship of Taro in­to a full takeover, pay­ing $43 a share in cash for shares that it doesn’t al­ready own. Ac­cord­ing to Kren­sav­age, the deal un­der­val­ues Taro by rough­ly 44%. — Kather­ine Lewin

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER